{"title": "UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19", "author": null, "url": null, "hostname": null, "description": null, "sitename": "2020 Archive - UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19", "date": "2017-05-15", "cleaned_text": "May 05, 2020 | [Joanne Morrison](mailto:jmorrison@som.umaryland.edu) Contact Joanne Morrison Director of Marketing and Public Relations Center for Vaccine Development and Global Health University of Maryland School of Medicine jmorrison@som.umaryland.edu Office: (410) 706-2884 Mobile: (202) 841-3369 Related stories Tuesday, December 20, 2022 [COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds](https://www.medschool.umaryland.edu/news/2022/COVID-Vaccines-Prevented-3-Million-Deaths-in-the-US-New-Analysis-Finds.html) In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund. Wednesday, February 16, 2022 [Study Shows New Drug Combination More Effective Against SARS-CoV-2](https://www.medschool.umaryland.edu/news/2022/Study-Shows-New-Drug-Combination-More-Effective-Against-SARS-CoV-2.html) Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually. Wednesday, January 26, 2022 [Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of \"Mix-and-Match\" COVID-19 Vaccine Booster Dosing](https://www.medschool.umaryland.edu/news/2022/Trial-Co-led-by-University-of-Maryland-School-of-Medicine-Scientist-Confirms-Safety-of-Mix-and-Match-COVID-19-Vaccine-Booster-Dosing.html) A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person's primary vaccine(s). Thursday, December 16, 2021 [Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers](https://www.medschool.umaryland.edu/news/2021/Novavax-COVID-19-Vaccine-Found-to-be-Safe-and-Effective-in-Phase-3-Trial-Conducted-by-UM-School-of-Medicine-Researchers.html) An investigational COVID-19 vaccine made by Novavax was found to be 90 percent effective at preventing COVID-19 illness, according to results from a Phase 3 clinical trial published today in the New England Journal of Medicine. The University of Maryland School of Medicine's (UMSOM) Center for Vaccine Development and Global Health served as one of the trial sites, and Karen Kotloff, MD, Professor of Pediatrics at UMSOM, served as Co-Chair for the trial protocol. Tuesday, December 14, 2021 [UM School of Medicine's Office of Public Affairs and Communications Honored with 2021 PRSA 'Best In Maryland' Award ](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicines-Office-of-Public-Affairs-and-Communications-Honored-with-2021-PRSA-Best-In-Maryland-Award-.html) The University of Maryland School of Medicine (UMSOM)'s Office of Public Affairs & Communications received the Public Relations Society of America (PRSA) 2021 \"Best in Maryland Award,\" the PRSA's highest honor, for its COVID-19 Communications program. The award was given at the PRSA Maryland Gala, held on December 9, 2021. Thursday, September 16, 2021 [First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever](https://www.medschool.umaryland.edu/news/2021/First-Efficacy-Results-from-Africa-find-Typhoid-Vaccine-to-offer-84-Percent-Protection-against-Typhoid-Fever.html) A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) - the only typhoid vaccine licensed for children as young as 6 months - is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV. Wednesday, September 08, 2021 [UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Reaching-Underserved-Communities-Through-Grass-Roots-Efforts-to-Increase-COVID-19-Vaccination-Rates.html) In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia. Wednesday, July 07, 2021 [UM School of Medicine Researchers Develop Two Rapid Tests for COVID-19 Using Innovative Techniques ](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Researchers-Develop-Two-Rapid-Tests-for-COVID-19-Using-Innovative-Techniques-.html) Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods. Wednesday, June 09, 2021 [Global Study of Microbes in 60 Cities Finds Each Has Unique Fingerprint of Viruses and Bacteria](https://www.medschool.umaryland.edu/news/2021/Global-Study-of-Microbes-in-60-Cities-Finds-Each-Has-Unique-Fingerprint-of-Viruses-and-Bacteria.html) Each city has its own unique microbiome, a \"fingerprint\" of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell. Tuesday, March 16, 2021 [New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel](https://www.medschool.umaryland.edu/news/2021/New-Study-Finds-Healthcare-Settings-Do-Not-Pose-Added-Risk-Factor-for-Covid-19-Infection-Spread-Among-US-Healthcare-Personnel.html) Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities. Wednesday, January 27, 2021 [Dr. Wilbur Chen, Nationally-Recognized Vaccine Researcher, Selected for Federal Committee that Guides Immunization Policies](https://www.medschool.umaryland.edu/news/2021/Dr-Wilbur-Chen-Nationally-Recognized-Vaccine-Researcher-Selected-for-Federal-Committee-that-Guides-Immunization-Policies.html) Wilbur H. Chen, MD, MS, FIDSA, FACP, Professor of Medicine at the University of Maryland School of Medicine (UMSOM), has been named a new voting member of the federal government's Advisory Committee on Immunization Practices (ACIP), the prestigious board of experts that makes recommendations on the safe use of vaccines for Americans. The U.S. Department of Health and Human Services selected Dr. Chen for the 15-member advisory committee based on his expertise and national leadership in vaccinology, infectious diseases, public health, and preventive medicine. He will remain in his current role at UMSOM while he serves in his four-year term, which began last month. Thursday, January 21, 2021 [UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Hosted-Media-Availability-for-Ensuring-Trust-in-COVID-19-Vaccine-Event.html) On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and \"America's Doctor,\" Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research. Tuesday, January 05, 2021 [Dr. Kathleen Neuzil, World-renowned Leader in Moderna Vaccine](https://www.medschool.umaryland.edu/news/2020/Dr-Kathleen-Neuzil-World-renowned-Leader-in-Vaccine-Research-Receives-Moderna-Vaccine.html) Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine's (UMSOM)'s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December. Tuesday, January 05, 2021 [University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Begins-Phase-3-Trial-of-Novavax-COVID-19-Vaccine-Candidate.html) Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD. Thursday, November 19, 2020 [Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine](https://www.medschool.umaryland.edu/news/2020/Promising-Results-Seen-in-PfizerBioNTech-COVID-19-Vaccine-After-Phase-1-Trial-by-University-of-Maryland-School-of-Medicine.html) Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19. Friday, November 13, 2020 [UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-and-School-of-Pharmacy-Researchers-Identify-Promising-New-Compounds-to-Potentially-Treat-Novel-Coronaviruses.html) Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal. Tuesday, June 16, 2020 [UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Receive-Federal-Funding-to-Rapidly-Test-New-Treatments-for-COVID-19.html) Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government's Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort. Tuesday, June 02, 2020 [UM School of Medicine's Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicines-Institute-of-Human-Virology-Awarded-Grants-to-Strengthen-COVID-19-Response-in-Sub-Saharan-Africa.html) The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine's Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique. Monday, June 01, 2020 [In A COVID-19 World, Another Threat to the Health of Our Children](https://www.medschool.umaryland.edu/news/2020/In-A-COVID-19-World-Another-Threat-to-the-Health-of-Our-Children.html) In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations. Thursday, May 28, 2020 [UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Develop-Experimental-Rapid-COVID-19-Test-Using-Innovative-Nanoparticle-Technique.html) Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society's nanotechnology journal ACS Nano. Thursday, May 21, 2020 [UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Begins-First-Innovative-Trial-of-Experimental-Stem-Cell-Therapy-to-Reduce-Deaths-in-Sickest-COVID-19-Patients.html) Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC. Thursday, April 23, 2020 [UM School of Medicine Researchers Test Remdesivir as Potential Therapy for COVID-19 Patients](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Test-Remdesivir-as-Potential-Therapy-for-COVID-19-Patients.html) Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Friday, April 10, 2020 [University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Launches-New-Large-Scale-COVID-19-Testing-Initiative.html) University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland. Wednesday, April 01, 2020 [Important Coronavirus Update from Dean Reece 04-01](https://www.medschool.umaryland.edu/news/2020/Important-Coronavirus-Update-from-Dean-Reece-04-01.html) I am sure you are aware of Governor Hogan's Executive Order that requires all residents of Maryland to stay at home, except for essential activities. The Governor continues to emphasize that we are still just at the beginning of this crisis in Maryland. While the State has been taking the lead with early containment efforts, we are now at a critical point. Each of our actions can lessen the expected surge in cases over the next few weeks. Wednesday, March 25, 2020 [Kids & COVID-19 Website Provides Resources for Pediatric Healthcare Providers and Families](https://www.medschool.umaryland.edu/news/2020/Kids--COVID-19-Website-Provides-Resources-for-Pediatric-Healthcare-Providers-and-Families.html) The University of Maryland School of Medicine has launched a special COVID-19 website for pediatric healthcare providers and practices, parents, and children. This resource brings together important research, professional guidance for pediatric practices, and practical tips for parents and caregivers. Wednesday, March 25, 2020 [Important Coronavirus Update from Dean Reece](https://www.medschool.umaryland.edu/news/2020/Important-Coronavirus-Update-from-Dean-Reece.html) As we continue to move forward in these challenging times, I would like to bring you a message of encouragement and hope. First and foremost, please be assured and confident that we are, and will continue to do, everything we can to ensure the health and well-being of all within our community. As you will see in this briefing, significant steps are being taken by the State of Maryland, the University of Maryland Medical System and the University of Maryland, Baltimore to ensure that everyone is healthy and safe. We must each do whatever is necessary to ensure that our health comes first. Tuesday, February 25, 2020 [Washington Post Visits UM School of Medicine Laboratories, Meets with Scientists About Coronavirus](https://www.medschool.umaryland.edu/news/2020/Washington-Post-Visits-UM-School-of-Medicine-Laboratories-Meets-with-Scientists-About-Coronavirus.html) Result is front-page feature coverage of UMSOM's leading work in studying the Virus Wednesday, January 29, 2020 [University of Maryland School of Medicine Mobilizes Virus Experts to prepare for Potential Coronavirus Outbreak](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Mobilizes-Virus-Experts-to-prepare-for-Potential-Coronavirus-Outbreak.html) As public health officials around the world are monitoring a new coronavirus strain (2019-nCoV) first identified in the Wuhan City, Hubei Province, China, the University of Maryland School of Medicine (UMSOM) is mobilizing its physicians and scientists in the UMSOM's Center for Vaccine Development and Global Health (CVD), and in its Department of Microbiology & Immunology, to study the virus and test potential vaccines and other therapies. In addition, the UMSOM is collaborating with the University of Maryland Medical Center (UMMC) on rapid response and preparedness planning in the event of a growing outbreak. Monday, May 15, 2017 [UM SOM Vaccine Researcher Receives Top Award in the Study of Infectious Diseases](https://www.medschool.umaryland.edu/news/2017/UM-SOM-Vaccine-Researcher-Receives-Top-Award-in-the-Study-of-Infectious-Diseases.html) Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Disease at UM SOM, has been awarded the Maxwell Finland Award for Scientific Achievement by the National Foundation for Infectious Diseases (NFID). The award honors his extensive accomplishments in public health; over his career, he has identified solutions to major sources of disease in the developing world, including cholera, typhoid, and Shigella dysentery. The award will be presented on Thursday, May 18, 2017 at the Hyatt Regency Bethesda in Bethesda, Md. "}